Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Update

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 3,033 shares, a growth of 85.7% from the June 30th total of 1,633 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 65,515 shares, the short-interest ratio is presently 0.0 days.

Emmaus Life Sciences Stock Performance

Shares of OTCMKTS:EMMA remained flat at $0.01 during trading on Friday. 50 shares of the stock were exchanged, compared to its average volume of 16,760. The firm’s 50-day moving average price is $0.01 and its 200-day moving average price is $0.01. Emmaus Life Sciences has a 1 year low of $0.01 and a 1 year high of $0.02. The company has a market capitalization of $701,880.00, a PE ratio of -0.08 and a beta of 9.06.

Emmaus Life Sciences (OTCMKTS:EMMA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.05) earnings per share for the quarter. The company had revenue of $1.98 million for the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.